Abstract 271P
Background
To assess the cost-effectiveness of pembrolizumab monotherapy (P) for CPS ≥1 subpopulation and in combination with platinum+5-FU chemotherapy (P+C) for the overall population versus cetuximab+platinum+5-FU chemotherapy (EXTREME regimen: E) for the first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in Taiwan.
Methods
A cohort-based partitioned survival model consisting of three health states (progression-free, progressed disease, and death) was developed. Using overall survival and progression free survival data from the P and P+C vs E arms of the KEYNOTE-048 study, the proportion of patients in each health state was estimated by parametric modeling over a 10-year period. Healthcare resource utilization data and costs per unit were sourced from the Taiwan National Healthcare Insurance Research Database, Cancer Registry database based on Taiwan National Health Insurance Administration (NHIA) reimbursement prices.
Results
In the base case analysis, P and P+C resulted in higher costs vs E (P: $1,964,859 vs E: $1,200,788 in the CPS ≥1 population; P+C: $2,301,474 vs E: $1,236,156 in the overall population), and higher quality adjusted life years (QALYs: P:1.22 vs 0.73 in the CPS ≥1 population; P+C: 1.30 vs 0.74 in the overall population). The incremental cost effectiveness ratio (ICER) for P vs E was NT$1,571,914/QALY in the CPS ≥1 population, and NT$1,912,195/QALY for P+C vs E in the overall population, respectively. At a willingness-to-pay threshold of 3 times Taiwan per capita Gross Domestic Product (GDP: NT$2,309,934), the resultant incremental cost/QALY for both P and P+C are considered cost-effective.
Conclusions
Both P and P+C are projected to be cost-effective options compared with E for the first-line treatment of R/M HNSCC patients. These results reflect the assumption of the publicly known pembrolizumab price in Taiwan; the price under managed entry agreement with NHIA may result in lower ICERs further demonstrating greater cost-effectiveness value.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MSD LLC Taiwan Branch, Taiwan.
Funding
MSD LLC Taiwan Branch, Taiwan.
Disclosure
C.H. Wang: Advisory/Consultancy: Merck Sharp & Dohme (I.A.) LLC Taiwan Branch. All other authors have declared no conflicts of interest.
Resources from the same session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session